Preclinical study demonstrates enhanced tumor inhibition in hepatocellular carcinoma models using biomimetic nanovesicles, suggesting a potent multi-reactive species cancer therapy.
Reactive species chemistry, encompassing both broad-spectrum reactive oxygen species (ROS) and reactive nitrogen species (RNS), has received significant attention in cancer therapeutics due to its capacity to induce severe oxidative damage and subsequent cancer cell death. Here in this study, we developed M1 macrophage membrane-coated MnO2-silica containing doxorubicin (DOX) and NO donor (M1@MS/MnO2/DOX/NO) for the combination of reactive species, including both ROS and RNS for hepatocellular carcinoma therapy. Specifically, superoxide anion O2•– produced from DOX could react with NO to form ONOO– for RNS-mediated treatment. Meanwhile, Mn2+ produced from the MnO2 layer under a reductive microenvironment could function as a catalyst to transform endogenous H2O2 into the highly toxic •OH to achieve ROS-mediated treatment. Our results demonstrated that this novel combination of reactive species therapy synergistically improved the therapeutic efficiency against liver cancer cells, and showed a significant reduction of cancer cell proliferation and in vivo tumor growth.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: